UNI-EN 37:Decision by the European Commission regarding perindopril
Firma: KRKA, TOVARNA ZDRAVIL D.D.Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| | UNI - EN REPORT No | 37 | / | 2014 | | ||||||
| Date of issue: | 2014-07-09 | ||||||||||
| Short name of the issuer | |||||||||||
| KRKA | |||||||||||
| Subject | |||||||||||
| Decision by the European Commission regarding perindopril | |||||||||||
| Official market - legal basis | |||||||||||
| Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| See the attached document. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| EU Commission.pdf EU Commission.pdf | EC decision perindopril case | ||||||||||
| KRKA, TOVARNA ZDRAVIL D.D. | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| KRKA | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 8501 | Nove Mesto | ||||||||||||
| (post code) | (city) | ||||||||||||
| Smarjeska | 6 | ||||||||||||
| (street) | (number) | ||||||||||||
| +386 7 331 21 11 | +386 7 332 15 37 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nie dotyczy | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2014-07-09 | Joze Colaric | President of Management Board and CE | |||
Cena akcji Krka
Cena akcji Krka w momencie publikacji komunikatu to 225.0 PLN. Sprawdź ile kosztuje akcja Krka aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Krka.
